Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Patel JD, et al. Among authors: beck t. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145346 Free PMC article. Clinical Trial.
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Krill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, Tai F, Marciniak MD, Obasaju C, Hainsworth J. Brufsky A, et al. Among authors: beck t. Clin Breast Cancer. 2011 Aug;11(4):211-20. doi: 10.1016/j.clbc.2011.03.019. Epub 2011 Jul 1. Clin Breast Cancer. 2011. PMID: 21723792 Clinical Trial.
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Borson R, et al. Among authors: beck t. Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004. Clin Breast Cancer. 2012. PMID: 23040000 Clinical Trial.
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Hanna N, et al. Among authors: beck t. J Clin Oncol. 2006 May 1;24(13):2038-43. doi: 10.1200/JCO.2005.04.8595. J Clin Oncol. 2006. PMID: 16648503 Clinical Trial.
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Mani S, et al. Among authors: beck t. J Clin Oncol. 2000 Aug;18(15):2894-901. doi: 10.1200/JCO.2000.18.15.2894. J Clin Oncol. 2000. PMID: 10920138 Clinical Trial.
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM. Goodman GE, et al. Among authors: beck tm. J Clin Oncol. 1990 Jan;8(1):39-47. doi: 10.1200/JCO.1990.8.1.39. J Clin Oncol. 1990. PMID: 2153194 Clinical Trial.
1,313 results